SCHEMBL1506370

SCHEMBL1506370

O=C[C@H]1C[C@@H](c2ccc(Br)cc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 6/20 0.42
MAOB P27338 3/20 0.42
KCNH2 Q12809 2/20 0.42
RCOR1 Q9UKL0 2/20 0.42
KDM1B Q8NB78 1/20 0.42
BRD4 O60885 1/20 0.41
HTR2C P28335 2/20 0.37
HTR2B P41595 2/20 0.37
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
SLC18A3 Q16572 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
LIG1 P18858 1/20 0.33
CYP2A6 P11509 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506335 1.00 KDM1A (0.42) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL1506333 1.00 KDM1A (0.42) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL6665053 0.82 HDAC2 (0.41) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL16761996 0.79 KDM1A (0.42) KDM1AHTR2CHTR2BSLC18A3SIGMAR1
SCHEMBL19294269 0.79 MAP1LC3B (0.42) HTR2CHTR2BMEN1KMT2ASLC18A3
SCHEMBL16761993 0.79 KDM1A (0.42) KDM1AHTR2CHTR2BSLC18A3SIGMAR1
SCHEMBL16761873 0.78 GAA (0.43) KDM1AMAOBKCNH2RCOR1BRD4
SCHEMBL16762030 0.78 GAA (0.43) KDM1AMAOBKCNH2RCOR1BRD4
SCHEMBL16761874 0.78 GAA (0.43) KDM1AMAOBKCNH2RCOR1BRD4
SCHEMBL6463686 0.77 KDM1A (0.34) KDM1AMAOBKCNH2RCOR1KDM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3191445-B1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2019-06-12 EP disclosed
EP-3191445-B1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2019-06-12 EP disclosed
US-10023519-B2 Cyclobutane containing carboxylic acid GPR120 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2018-07-17 US disclosed
US-10023519-B2 Cyclobutane containing carboxylic acid GPR120 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2018-07-17 US disclosed
US-10023519-B2 Cyclobutane containing carboxylic acid GPR120 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2018-07-17 US disclosed
US-20170247311-A1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2017-08-31 US disclosed
US-20170247311-A1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2017-08-31 US disclosed
US-20170247311-A1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2017-08-31 US disclosed
EP-3191445-A1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS Bristol-Myers Squibb Company (US) 2017-07-19 EP disclosed
WO-2016040223-A1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-17 WO disclosed
EP-1888523-B1 CYCLOBUTYL AMINE DERIVATIVES ABBOTT LAB (US) 2011-10-26 EP disclosed
EP-2298734-A2 Cyclobutyl amine derivatives Abbott Laboratories (US) 2011-03-23 EP disclosed
US-20090227593-A1 CYCLOBUTYL AMINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-09-10 US disclosed
US-7553964-B2 Cyclobutyl amine derivatives ABBOTT LABORATORIES (US) 2009-06-30 US disclosed
US-20070078133-A1 Cyclobutyl amine derivatives ABBVIE INC. 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023519-B2 Cyclobutane containing carboxylic acid GPR120 modulators GPR68, GPR88, GPR55 KDM1A 4157/4885MAOB 3081/4885KCNH2 2220/4885
US-20090227593-A1 CYCLOBUTYL AMINE DERIVATIVES HRH2, HRH4, HRH3 KDM1A 3406/4885MAOB 103/4885KCNH2 1616/4885
US-20070078133-A1 Cyclobutyl amine derivatives HRH2, HRH4, HRH3 KDM1A 3406/4885MAOB 103/4885KCNH2 1616/4885
US-20170247311-A1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS GPR68, GPR88, GPR55 KDM1A 4157/4885MAOB 3081/4885KCNH2 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.